Journey Medical Q2 Revenue Jumps 23%, Loss Narrows to $0.3M
DERM sits 53% above its 52-week low of $4.31.
Summary
Journey Medical reported Q2 revenue of $18.5M, up 23% year-over-year and slightly above the $18.37M consensus. Net loss narrowed dramatically to $0.3M from $3.8M a year ago, driven by strong Emrosi demand and disciplined cost management. The company highlighted increasing prescriptions and payer coverage for Emrosi, its key dermatology product. This follows a Q1 report that also showed strong growth and reduced losses, though a going concern warning remains. The stock trades at 10x forward earnings versus 13x three months ago, with a median analyst price target of $13.00, suggesting significant upside if execution continues.
At the time of this announcement, DERM was trading at $6.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $177M. The 52-week trading range was $4.31 to $9.56. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.